News

Cross Country Healthcare (CCRN) reported $236.76 million in revenue for the quarter ended December 2025, representing a year-over-year decline of 23.6%. EPS of -$0.06 for the same period compares to $0.04 a year ago.

The reported revenue represents a surprise of -6.14% over the Zacks Consensus Estimate of $252.25 million. With the consensus EPS estimate being $0.03, the EPS surprise was -300%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Cross Country performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Nurse and allied staffing statistical data - FTEsn: 6,318 versus 6,535 estimated by two analysts on average.
• Physician staffing statistical data - Revenue per day filled: $2,286.00 versus $2,053.50 estimated by two analysts on average.
• Physician staffing statistical data - Days filled in HRS: 18,599 versus the two-analyst average estimate of 16,832.
• Revenue- Physician staffing: $42.52 million versus $49.66 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -19.8% change.
• Revenue- Nurse and allied staffing: $194.24 million versus the three-analyst average estimate of $203.75 million. The reported number represents a year-over-year change of -24.4%.

Shares of Cross Country have returned -0.2% over the past month versus the Zacks S&P 500 composite's -1.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Free Report: Profiting from the 2nd Wave of AI Explosion

The next phase of the AI explosion is poised to create significant wealth for investors, especially those who get in early. It will add literally trillion of dollars to the economy and revolutionize nearly every part of our lives.

Investors who bought shares like Nvidia at the right time have had a shot at huge gains.

But the rocket ride in the "first wave" of AI stocks may soon come to an end. The sharp upward trajectory of these stocks will begin to level off, leaving exponential growth to a new wave of cutting-edge companies.

Zacks' AI Boom 2.0: The Second Wave report reveals 4 under-the-radar companies that may soon be shining stars of AI’s next leap forward.

Access AI Boom 2.0 now, absolutely free >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.